Navigation Links
Mylan Launches Generic Version of Zyprexa® Tablets
Date:4/24/2012

PITTSBURGH, April 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Olanzapine Tablets USP, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg. This product is the generic version of Eli Lilly and Company's Zyprexa®, which is indicated for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar 1 disorder and maintenance treatment of bipolar 1 disorder. [1]

Olanzapine Tablets USP, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg, had U.S. sales of approximately $3.3 billion for the 12 months ending Dec. 31, 2011, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 171 ANDAs pending FDA approval representing $97.2 billion in annual sales, according to IMS Health. Forty of these pending ANDAs are potential first-to-file opportunities, representing $25.7 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

[1] There is an increased
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and LYON, France , Dec. ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ... developing an ultra-rapid insulin, known as BioChaperone Lispro, for ... diabetes. BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology ... Lilly and Adocia will develop BioChaperone Lispro with the ...
(Date:12/17/2014)... , December 17, 2014 Revenue and ... expenditure on research and development In the past ... revenue by two percent to EUR 4.287 billion (last year: ... by 14 percent to EUR 360 million. "Overall, 2013/14 was ... Michael Kaschke , President and CEO of Carl Zeiss ...
(Date:12/17/2014)... Ariz. , Dec. 17, 2014  Beamz ... state-of-the-art interactive music products, today announced that it ... a leading manufacturer and supplier of innovative prosthetic, ... As part of the agreement, RSL Steeper ... bundled solution specifically configured for use within UK ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... NEWTOWN, Pa., Dec. 1, 2011 HeartSine ® Technologies, ... announced today that it is the exclusive provider of ... nation,s second largest nursing facility company. As part ... Access Defibrillator , HeartSine,s lifesaving product for the treatment ...
... (Nasdaq: MYL ) today announced that its ... received tentative approval from the U.S. Food and Drug ... Relief (PEPFAR) for its New Drug Application (NDA) for ... This product is the first heat-stable, fixed-dose ...
Cached Medicine Technology:HeartSine® Technologies Now Exclusive Provider of Lifesaving AEDs to Golden LivingCenters 2HeartSine® Technologies Now Exclusive Provider of Lifesaving AEDs to Golden LivingCenters 3Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS 2
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
(Date:12/19/2014)... 20, 2014 Today, Balfleet.com , ... outfits, announces its formal dress promotion. All the old ... to 60% off. , Balfleet.com is well-known for its ... dresses, prom dresses, cocktail dresses and more. Its formal ... money-back guarantee, and they can create an elegant look ...
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... 19, 2014 Eufaula, Oklahoma, located just ... Eufaula, the state’s largest lake with more than 600 ... home to a little more than 3,000 residents, hosted ... Saturday, the 6th of December. , Featuring Santa, Christmas ... downtown Eufaula on Main Street. Narconon Arrowhead’s parade ...
(Date:12/19/2014)... December 20, 2014 The print component ... and Business subscription of the Toronto Star, with a ... of 622,169. The digital component is distributed nationally through ... of top news sites and partner outlets. To explore ... . , The publication features an exclusive interview ...
Breaking Medicine News(10 mins):Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2
... Service Corporation,s Technology Investments Streamline ... HealthLeaders-InterStudy, NASHVILLE, Tenn., Aug. 5 ... intelligence, reports that Health,Care Service Corporation is ... serve its members. According to the,new report ...
... (Nasdaq: NKTR ) today announced the company,s financial ... 2008., Cash, cash equivalents, and short-term investments were ... at March 31, 2008., Revenue for the three ... to revenue of $65.9 million in the second quarter ...
... 6 Nektar,Therapeutics (Nasdaq: NKTR ) today ... the position of Senior Vice President of Drug,Development ... Dr.,Moreadith will report to Nektar,s President and Chief ... lead Clinical Drug Development, Clinical,Pharmacology and Toxicology, and ...
... 9.3 percent (constant currency) - Execution of strategic ... guidance based on year-to-date ... performance and operational momentum, BATESVILLE, Ind., Aug. 6 ... results for its fiscal,third quarter ended June 30, 2008 -- ...
... Pa., Aug. 6 West Pharmaceutical,Services, Inc. (NYSE: ... Vice,President and Chief Financial Officer, and Michael Anderson, ... will be presenting at,the CJS Securities 8th Annual ... NY, on August 12, 2008. A copy of ...
... A drug-like molecule called Wnt can be substituted for ... to adult cells to reprogram them to an embryonic-stem-cell-like ... embryonic stem-cell-like cells, known as induced pluripotent (IPS) cells, ... diabetes. , Demonstrated in mice, the elimination of ...
Cached Medicine News:Health News:Insurance Giant Leverages Technology to Enhance Offerings 2Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 2Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 3Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 4Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 5Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 6Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 7Health News:Nektar Therapeutics Announces Second Quarter 2008 Results 8Health News:Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer 2Health News:Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer 3Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 2Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 3Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 4Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 5Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 6Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 7Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 8Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 9Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 10Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 11Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 12Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 13Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 14Health News:Recipe for cell reprogramming adds protein 2
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... Delivering optimum performance with maximum comfort, ... for medical professionals worldwide. All SheerVision ...
... Experience the finest surgical-quality loupes available ... the standard for innovative optical design, ... Delivering optimum performance with maximum comfort, ... for medical professionals worldwide. Make both ...
... SheerVision have addressed a key need of ... with light-weight comfort for everyday use. ... as 1.5 ounces when included with a ... either a flip-up or through-the-lens (TTL) design. ...
Medicine Products: